drugset / Trial / NCT06221826

MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure

NCT06221826

Phase 4 Completed 60 enrolled Pharmasoft
RandomizedParallel-groupOpen-labelTreatment

Summary

The use of metabolic modulators creates prospects for increasing the efficiency of the rehabilitation treatment of patients with acute cerebral failure

Timeline

Start
2023-04-17
Primary completion
2023-09-12
Completion
2023-09-12

Drugs

EvaluationDrugModalityDoseRoute
Subject EMOXYPINE Small molecule 250 mg Intravenous

Indications